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Make Love, Not War 

ABSTRACT 
 
The prevalence of sexually transmitted infections (STI) is high in the adult populations world-
wide but varies between populations and time periods. Since a high proportion of infected 
individuals are asymptomatic, diagnostic approaches to reduce further transmission and 
complications are essential. 
 
The three main topics of this thesis are (1) the prevalence of the herpes viruses: herpes 
simplex type 1 (HSV-1) and type 2 (HSV-2), Epstein-Barr virus (EBV) and cytomegalovirus 
(CMV) in different populations; (2) the clinical spectrum of genital infection with HSV-2; and 
(3) the connection between different criteria of cervicitis and female urethritis and a positive 
chlamydia test.  
 
Herpes simplex virus type 2 infections, diagnosed by type-specific serology, were common in 
both STI patients and pregnant women. Of the pregnant women 10% were seropositive for 
HSV-2, and of female and male STI patients 23% and 12% had HSV-2 antibodies, 
respectively. Infection with HSV-2 was often asymptomatic and only 41% of seropositive 
patients had a history of genital herpes. Atypical manifestations, so-called unrecognised 
infections, were common and are of clinical importance.  
 
Among 112 male patients with urethritis no cases of herpes simplex virus were found. 
Instead, Epstein-Barr virus was detected by PCR in urethral samples in a significantly higher 
proportion of the subjects than in the controls (21% vs. 6%). EBV was also detected in 10.5% 
of cervical samples from young women attending for Cervical Cancer Screening. In a similar 
proportion of these women, 11.5%, cytomegalovirus was found in the cervical specimens. 
 
In female STI patients a significant correlation with a positive C. trachomatis test was shown 
for mucopurulent discharge in the cervical portio, for easily induced bleeding from the same 
locus, and for more polymorph nuclear leucocytes (PMNL) than epithelial cells in the vaginal 
wet smear. However, no correlation was demonstrated between microscopical cervicitis or 
urethritis and C. trachomatis. 
 
In conclusion, diagnostic tests for HSV-2 should be performed generously in patients with 
recurring genital symptoms of unknown cause. The detection of EBV in urethral samples 
from men with urethritis and the demonstration of EBV and CMV in the cervix of young 
women support genital transmission of these viruses. Epstein-Barr virus was significantly 
correlated to male urethritis, which has not been demonstrated previously. However, further 
studies are needed to elucidate a possible causality between EBV and urethritis. Since an 
elevated number of PMNL in stained smears from the cervix or the urethra was not correlated 
with a positive test for C. trachomatis, routine sampling for microscopy from these loci in 
unselected female STI patients is questionable. 
 
 
 
Key words: Herpes simplex virus, seroprevalence, Epstein-Barr virus, cytomegalovirus, 
urethritis, cervicitis, Chlamydia trachomatis, STI 
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INTRODUCTION 
 
The term “sexually transmitted infections” (STI) encompasses infections caused 
by a broad range of pathogens, including viruses, bacteria and protozoa. The 
transmission route of these infections is sexual contact between human beings. 
The number of known STI is about thirty and the prevalence of chronic viral STI 
such as herpes simplex virus infections and human papilloma virus infections is 
very high in the adult populations world-wide. The highest incidence rates of 
STI are generally found in urban populations between the ages of 15 and 35. It is 
not unlikely that the majority of adults in the world have one or more STI (1). 
Since many of these infections are asymptomatic, the term STI is preferable to 
the formerly used STD (sexually transmitted diseases). 
 
This research work began with epidemiological studies of herpes simplex virus 
type 2 in STI patients and pregnant women (papers I-II). The starting point of 
the study of male urethritis (paper III) was the question to what extent herpes 
simplex virus is an etiological agent in urethritis. The results showed no cases of 
herpes simplex virus but instead a relatively high proportion of men with 
Epstein-Barr virus. The next step was to investigate the occurrence of the 
different herpes viruses, including Epstein-Barr virus, in the uterine cervix of 
young women (IV). The last study (V) comprises STI patients with cervicitis, 
the female counterpart to urethritis in men. The driving forces for this study 
were the lack of established criteria for cervicitis in combination with a growing 
interest in health economy. 
 
 
Viral agents 
 
Herpes viruses 
Herpes simplex virus type 1 and type 2 (HSV-1 and HSV-2), varicella zoster 
virus (VZV), cytomegalovirus (CMV) and Epstein-Barr virus (EBV) all belong 
to the herpesviridae. This family consists of large double-stranded DNA viruses 
with an icosahedral capsid. Outside the capsid is an amorphous layer of viral 
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proteins called the tegument surrounded by a lipid bilayer envelope containing 
viral glycoproteins. The ability to reactivate after period/periods of latency is a 
common feature, but otherwise the biology and the clinical pictures of the 
produced infections vary between the different herpes viruses. The most severe 
infections are seen in immunocompromised patients. Three subfamilies, alpha-, 
beta- and gamma-herpesviridae, have been classified according to details of 
replication, the cells in which they establish latency, gene content and gene 
organization. HSV-1, HSV-2 and VZV constitute the alpha-herpesviruses and 
establish latent infection in dorsal root ganglia. 
 
Herpes simplex type 1 and type 2 
Herpes simplex viruses are large double-stranded DNA viruses. Outside the core 
of viral DNA is an icosahedral capsid surrounded by an envelope, in which 
glycoproteins necessary for viral entry are located. All glycoproteins in the 
envelope induce antibody production. There is a high degree of homology 
between the glycoproteins in HSV-1 and HSV-2 and the only known type-
specific antibody responses are the ones directed against glycoprotein G1 (gG-1) 
and glycoprotein G2 (gG-2). 
 
HSV is transmitted through damaged skin and intact mucosa. Following entry 
both HSV-1 and HSV-2 infect nerve endings and through the neuronal axons the 
viruses reach the neuronal nuclei, where latency is established. In mice the rate 
of reactivation has been correlated to the number of latently infected neurons in 
the ganglia (2). Latent HSV infection in humans causes a chronic inflammation 
without signs of neuronal destruction (3). During the latency phase the virus 
persists either in a true latent state or in a condition of low-level replication. 
HSV-1 predominates in oro-facial lesions and is commonly found in the 
trigeminal ganglia, whereas HSV-2 is often located in the sacral root ganglia. 
Reactivation leads to transport of the virus through the axon back to the 
epithelial cells of the skin or mucosa producing prodromal symptoms, clinical 
lesions or subclinical shedding. Described triggers are sun-light exposure (HSV-
1), psychosocial stress (4), hormonal factors (menstruation), fever, infections, 
immunosuppression and mechanical friction. 
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Fig.1. Age-related seroprevalence of HSV-2 in the Swedish general population in 1990-91 
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Fig.2. Age-related seroprevalence of HSV-1 in the Swedish general population in 1990-91 
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Source to Fig. 1-2 : Tunbäck 2004 (5) 
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Epidemiology 
Genital herpes (GH) is one of the most widely spread sexually transmitted viral 
diseases and is caused by HSV-2 and HSV-1. The seroprevalence of HSV-2 is 
used as a marker for genital herpes, whereas HSV-1 antibodies reflect oro-labial 
and/or genital herpes. 
 
In childhood and adolescence the HSV-2 seroprevalence is very low. It rises 
with increasing age after coitarche until about 40 years of age (6). Older age and 
female sex are factors associated with a higher seroprevalence of HSV-2. The 
age-related seroprevalence of HSV-2 in the Swedish general population in 1990-
91 is shown in Figure 1 (5). The frequency of HSV-2 antibodies is higher in 
patients attending STI clinics than in the general population, with figures from 
17% in Italy (7) to 40% in a study from Australia (8). Indeed, there is a 
correlation to sexual behaviour, especially to the number of sexual partners (9). 
In addition, ethnicity and low socio-economic status are known risk factors for 
HSV-2. The highest reported seroprevalence of HSV-2 in Sweden, 39%, has 
been found in middle-aged women who were teenagers during the 1960s, a 
decade when the incidence of gonorrhoeae was high as well (10). The 
occurrence of HSV-2 antibodies is higher in sub-Saharan Africa than in other 
developing countries with a prevalence of 30-80% in women and 10-50% in 
men (11). In Asia the prevalence in the general population is lower, between 10-
30% (12). 
 
Regarding HSV-1 the major transmission route is by transfer of saliva during 
childhood and the seroprevalence increases with age. The age-related 
seroprevalence of HSV-1 in the general population in Sweden 1990-90 is shown 
in Figure 2 (5). In recent years HSV-1 infection during childhood has decreased 
in many countries (13) and the proportion of first episodes of genital herpes 
caused by HSV-1 is increasing, especially shown in young women (14, 15). In 
the US the proportion of GH caused by HSV-1 in the age group 16-21 years of 
college students was 78% in 2001 compared to 31% ten years earlier (15). This 
increase has been attributed to change in sexual behaviour. In a report from the 
National Institute of Public Health in 1997 oral sex was more frequently 
reported in younger age groups (16). Another explanation might be a higher 
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susceptibility in young adults due to a decrease in the seroprevalence of HSV-1 
(17). Also HSV-1 antibodies are to some extent correlated to low socio-
economic status and sexual behaviour (18). In the adult population 
seroprevalence figures vary from <=70% in northern Europe and non-black 
Americans to >85% in southern Europe and Africa (18). 
 
 
Clinical picture 
 
(1) First episode primary HSV infection (no HSV antibodies) 
Oro-labial herpes simplex: Clinical symptoms of primary oro-labial HSV 
infection vary from a mild local irritation or a few vesicles turning into crusts to 
gingivo-stomatitis with wide-spread ulcerations, lymphadenopathy, fever and 
malaise. Symptoms appear after an incubation period of 2-12 days (mean 4 
days) and excretion of virus can be detected for an average time of 7-10 days 
(19). 
 
Genital herpes simplex: After an incubation time of 2-20 days (mean 6 days) for 
both HSV-1 and HSV-2 the clinical picture ranges from mild erythema to 
vesicles, more often seen as ulcerations in the genital area, especially in the 
mucosa. Bilateral location of lesions is not uncommon. Extra-genital lesions on 
the buttocks, groins or thighs are more common in primary HSV-2 genital 
herpes, whereas concomitant lesions in the face are more common in genital 
herpes caused by HSV-1 (20). Primary anal and peri-anal localisation is 
particularly seen in men who have sex with men (MSM). Symptoms of systemic 
illness, like fever, malaise, urinary retention and lymphadenopathy, are more 
common in women than men (21). 
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(2) First episode non-primary HSV infection (antibodies against the other 
subtype of HSV) 
This designation is mainly used for HSV-1 seropositive patients, who acquire 
HSV-2 genital herpes. In this case the HSV-1 antibodies seem to modify the 
clinical picture, making the symptoms milder and of shorter duration (22). 
 
(3) Recurrent HSV infection 
A clinical recurrence of HSV infection is the appearance of symptoms due to 
reactivation of latent virus in the neural ganglia in a person with HSV 
antibodies. The clinical signs and symptoms are milder compared to the primary 
infection and subside faster. Prodromal symptoms such as itch, pain or a burning 
sensation occur 4-48 hours before clinical manifestations in about 50% of 
patients with GH. In oral HSV-1 infection vesicles commonly appear on the lip 
margin rapidly turning into dry crusts, which are usually completely healed in a 
week’s time in immunocompetent individuals. Recurrent episodes of genital 
herpes are mostly caused by HSV-2. In a Swedish study from 2001, 94% of 
cases of recurrent genital herpes were due to HSV-2 (23). Common 
manifestations of genital recurrences are unilateral vesicles or shallow ulcers in 
the genital area. Extra-genital lesions can occur, especially in patients with 
extra-genital location of lesions during the primary infection (20). Recurring 
fissures, erythema and oedema can be atypical manifestations of HSV-2 (24). 
The occurrence of clinical recurrences is dependent on both virus type and site 
of infection. The highest frequency of recurrences is seen in genital HSV-2 
infections, followed by oro-labial HSV-1, genital HSV-1 and oro-labial HSV-2 
(25). 
 
The chronic nature of genital herpes in combination with genital location, 
asymptomatic shedding of virus and unpredictable recurrences leads to 
psychosocial/psychosexual distress in many patients, especially those with 
HSV-2 (26, 27). 
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(4) Asymptomatic HSV infection ─ unrecognised infections 
The majority of HSV-1 and HSV-2 infections are asymptomatic or give non-
specific symptoms that are not recognized as herpes (28). In a prospective study 
of 2393 sexually active HSV-2 seronegative persons followed for 18 months, 
63% (98/155) of the newly acquired HSV-2 infections were asymptomatic. 
Asymptomatic seroconversion to HSV-2 was more common in men than 
women. Of 19 acquired HSV-1 infections, diagnosed by type-specific 
seroconversion or viral culture for HSV-1, 7 (37%) were asymptomatic (22). 
Another study by Langenberg et al. showed that approximately 50% of women 
with initially reported asymptomatic HSV-2 infection did in fact have clinical 
symptoms of GH (29). 
 
(5) Neonatal HSV infection 
Neonatal HSV infections can result from either HSV type 1 or 2. According to 
the literature 50-70% of the cases are caused by HSV-2 (30). Asymptomatic 
cervical shedding of virus during a primary infection in the mother is regarded 
as a main risk factor for HSV transmission to the neonate. The risk of vertical 
transmission has been estimated to 25-50% during a primary HSV-1 or HSV-2 
infection compared with a risk of <1% in women with longstanding HSV-2 
infection (31). Since recurrences are much more common than primary HSV 
infections, 30-50% of infants with neonatal herpes are born to mothers with 
established HSV infection, though in many cases unrecognised (1). Clinical 
manifestations of neonatal herpes infection ranges from disease localised to the 
skin, eye or mouth, to encephalitis and disseminated disease with high mortality 
(32). 
 
 
Viral shedding and transmission 
The most important factors for the transmission of genital herpes are 
asymptomatic shedding of HSV and unrecognised infections. A prospective 
study of 144 HSV-2 discordant heterosexual couples reported an annual 
seroconversion rate of 10% (33). In 11 of the 14 couples in which transmission 
occurred, the male was the source partner. The higher susceptibility to HSV-2 in 
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women than men has been shown in other studies and is partly explained by the 
larger exposed mucosal surface in women (34). In 69% of cases the transmission 
occurred without reported symptoms in the HSV-2 positive partner (33). In a 
prospective study of women with genital herpes, genital shedding was detected 
by virus isolation in 55% of HSV-2 infected women and 29% of women with 
HSV-1 genital herpes. Subclinical shedding of HSV-2 was shown on a mean of 
2% of the days (35). The detection rate of subclinical shedding is affected by the 
utilised test method, the number of anatomical sites sampled and the duration 
and frequency of sampling. 
With more sensitive PCR methods HSV DNA has been detected on up to 20% 
of days in women with HSV-2 genital herpes (36) and similar shedding data 
have been published for oral HSV-1 infection. Such high frequencies of HSV 
shedding support the view of HSV as a chronic rather than intermittent 
infection. 
 
A study from 2008 demonstrated that the frequency of symptomatic recurrences 
of GH was not related to the risk of transmission of HSV-2 to sexual partners 
(37). Analogously, in quantitative PCR analyses, the number of viral copies 
detected in subclinical reactivation is often as high as during symptomatic 
recurrences (1). 
 
Interaction between HSV-1 and HSV-2 
Previous infection with HSV-1 does not give protection against acquisition of 
HSV-2 GH, but implies a higher likelihood of asymptomatic seroconversion to 
HSV-2 (22), in most cases a milder first episode of GH, fewer symptomatic 
recurrences and less genital shedding of HSV-2 (38). However, a study of 
pregnant women reported a HSV-2 seroconversion rate during pregnancy in 
HSV seronegative women with HSV-2 positive partners of 33% compared to a 
5% risk in women with HSV-1 antibodies (39). A protective effect of genital 
HSV-2 against genital HSV-1 infection has also been proposed (40). 
 
Concurrent genital infections with HSV-1 and HSV-2 are occasionally seen and 
case reports have been published (41). 
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Prevention of HSV infections 
A pooled analysis of the effect of condom use in preventing acquisition of HSV-
2 demonstrated a moderate protective effect of condom use in both men and 
women with no gender differences. Individuals who reported a 100% use of 
condoms had a 30% lower risk of catching an HSV-2 infection compared with 
those who never used condoms (42). Vaccination remains the ideal method to 
prevent viral infections, but HSV vaccination trials have not yet succeeded. A 
delicate problem is the occurrence of recurrent episodes in the presence of 
specific antibodies. 
 
Educational efforts directed to populations at high risk of acquiring genital 
herpes are thought to be important in preventing HSV transmission. Type-
specific serological tests and polymerase chain reaction (PCR) tests, information 
and counselling to help patients identify atypical genital symptoms as 
recurrences of HSV infection might reduce the transmission rate. 
 
Diagnostic methods 
For the detection of herpes viruses in clinical specimens, molecular assays based 
on PCR amplification have been shown to be more sensitive and more specific 
than virus culture. However, culture methods are used to detect resistance to 
antiviral drugs, mostly seen in immunocompromised patients. 
 
Type-specific serological tests, based on glycoprotein G as antigen, are of value 
in patients with recurring genital symptoms, when the results of PCR tests for 
HSV have been negative. Some authors also recommend serological methods to 
find out whether a first-episode of GH is a primary infection or a first clinical 
recurrence (14, 22). The use of serological analyses of HSV in clinical practice 
is limited. However, the value of serology in epidemiological studies cannot be 
overestimated. 
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Treatment of HSV 
Acyclovir, valacyclovir and famciclovir are all effective drugs to reduce 
symptoms and the duration of symptoms in primary and recurrent episodes of 
genital infections with HSV. Antiviral therapy should be administered as soon as 
the first symptoms appear. 
 
Treatment of primary genital herpes does not affect the frequency or severity of 
recurrences. In patients with frequent recurrences long-term daily oral 
administration of the above-mentioned drugs reduces the number and the 
intensity of recurrent episodes. Although not an indication for treatment, 
valacyclovir has been shown to decrease transmission, when seropositive 
partners in HSV-2 discordant couples were treated (43). 
 
 
Cytomegalovirus (CMV) 
Cytomegalovirus is a large double-stranded DNA virus. The name is derived 
from the characteristic of this virus to enlarge the infected cells. CMV infects 
primarily leukocytes. The virus replicates for a long period in humans followed 
by latency and intermittent reactivation. The cellular site (s) of the latency phase 
is not fully elucidated, but endothelial cells and white blood cells are strong 
candidates (44, 45). 
 
Epidemiology/clinical picture 
Primary CMV infection is usually asymptomatic (77-100%) or associated with a 
mild mononucleosis-like illness. The incubation time is 4-8 weeks. Severe 
pneumonia and generalized, fatal infections are a threat to immunocompromised 
individuals (46). CMV pneumonitis and retinitis were feared complications in 
HIV patients before the introduction of highly-active antiretroviral therapy (44). 
A serious complication of CMV is congenital infection. Among newborns in 
Sweden about 0.5% have detectable CMV in the urine (47). Vertical 
transmission occurs both in women with primary CMV infection during 
pregnancy and in seropositive women with reactivation of the disease. About 
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80% of the children born with CMV are asymptomatic. Ten to twenty percent of 
neonatal infections with CMV result in neurological complications. 
 
In 4-year-old children in Sweden the prevalence of CMV antibodies was about 
40 % in 1998 (47) and the seroprevalence increases with age. The prevalence is 
higher in women than in men (48). Studies on pregnant women have shown 
CMV antibodies in 35-77% with higher prevalences in low-income groups (49). 
Reactivation of CMV during pregnancy due to hormonal factors has been 
reported (50). 
 
Transmission 
CMV has been detected in saliva, urine, breast milk (51), blood, cervical 
secretion and semen (52). Reported transmission routes of CMV are through 
saliva, droplet infection, blood transfusion, sexual contact and congenital or 
perinatal infection (44). Several reports have shown frequent transmission 
between children in day-care centers and from children to their caretakers. 
 
CMV as an STI 
Many studies have shown an association between CMV antibodies and sexual 
behaviour, such as early sexual debut, many sexual partners and occurrence of 
STI like chlamydia and gonorrhoeae (53, 54). No attempts have been made, 
however, to separate genital sexual practices from deep kissing, an activity 
undoubtedly associated with sexual activity and also with CMV transmission. 
The sexual transmission of HIV and HSV-2 has been shown to be more efficient 
from men to women than from women to men, partly explained by the larger 
exposed mucosal surface in women. Analogously, the higher seroprevalence of 
CMV in women than men at ages after coitarche compared with no reported 
gender difference during childhood is indicative of sexual transmission beyond 
oral-oral contact. Cervical CMV excretion was less frequent in women using 
barrier contraceptive methods (55). Coonrod et al. followed 608 CMV 
seronegative women in an STI clinic and of the 245 patients who seroconverted 
two women had CMV isolated from the genito-urinary tract before 
seroconversion suggesting genital transmission (53). Moreover, the 
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seroconverters were more likely to have symptoms and signs of upper genital 
tract infection, including cervical friability and cervical motion tenderness in 
absence of chlamydia and gonorrhoeae. CMV has been detected from 
endometrial samples in women with uterine bleeding and intrauterine device 
(56) and in chronic endometritis (57). CMV inclusion bodies have also been 
demonstrated in a recurrent vaginal ulcer (58) and in four cases of CMV 
cervicitis (cervical biopsies) (59). 
 
Diagnostic methods 
In clinical practice CMV is primarily detected by PCR methods. Quantification 
of DNA can be utilised to estimate the effect of antiviral treatment. Virus 
isolation is mainly used for estimation of antiviral drug resistance. Serological 
methods are useful, but a negative result does not rule out infection with CMV 
(44). 
 
Treatment  
Valacyclovir and ganciclovir are usually effective treatment against infection 
with CMV. Medical treatment is given to patients with severe infections. The 
use of ganciclovir/valganciclovir is sometimes limited due to haematological 
adverse effects. 
 
 
Epstein-Barr virus (EBV) 
EBV enters the body through mucosal surfaces and infects B cells, T cells, 
monocytes and epithelial cells (60). The virus then establishes a life-long latent 
infection in B lymphocytes, which become immortalised by the virus. 
 
Epidemiology/clinical picture 
Primary infection with EBV usually occurs subclinically during childhood and is 
correlated to low socio-economic status in the parents (60). Symptomatic 
infectious mononucleosis, also called “kissing disease”, appears mostly at ages 
15-25 years after an incubation period of about two weeks. EBV infection is 
associated with two malignant diseases: Burkitt’s lymphoma seen in Africans 
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with concurrent malaria infection, and nasopharyngeal carcinoma primarily seen 
in Chinese people in south-east China. Our knowledge of congenital EBV 
infections and possible effects on the foetus is insufficient. A prospective 
controlled study on 126 women with primary and recurrent EBV during 
pregnancy showed no significant teratogenic effects, but stated the need of 
further studies with a larger sample size (61). 
 
The reported prevalence of EBV antibodies in pre-adolescent children in 
developed countries is 40-80% (62). Between 7 and 14 years of age the 
prevalence is stable followed by a gradual increase during adolescence and early 
adulthood. The reported seroprevalence in teenage girls was 96% in the UK and 
82% in Sweden (63, 64). In adult populations world-wide the reported 
seroprevalence is more than 90-95% (60). 
 
Transmission 
The transmission between children is related to transfer of saliva during pre-
school years. A study of 24 healthy seropositive donors followed for 15 months 
demonstrated EBV shedding in the throat in 22/24 (92%) (65). 
 
Epstein-Barr virus as an STI 
Sexual activity has been identified as a significant risk factor for EBV 
seropositivity and infectious mononucleosis. Higgins et al. showed correlation 
of EBV to numerous sex partners and intercourse without a condom (66). 
Shared EBV strains between sexual partners have also been demonstrated (67). 
Besides in saliva EBV has been detected in genital secretions from the uterine 
cervix (68), the male urethra (67, 69) and in semen (52). In addition EBV has 
been demonstrated in vulvar mucosa (70), sulcus coronarius (68) and anal 
mucosa in homosexual HIV-positive men (71). Thomas et al. drew the 
conclusion that genital transmission is a minor route, based on the observation 
that the levels of EBV in genital secretions were lower than in saliva (67). 
Furthermore, fractionation of genital samples into cellular and supernatant fluid 
components revealed EBV to be mainly cell-associated, which might indicate 
passive transport in B-lymphocytes related to latent infection rather than active 
17 
viral replication. However, transmission of EBV via transfer of latently infected 
cells has been demonstrated in connection with blood transfusions (1). The 
detection of EBV in the genital area of both sexes supports genital transmission 
of this virus. As described for CMV, the higher frequency of EBV in women 
than men at ages after coitarche, compared to no difference between the sexes 
during childhood, is indicative of sexual transmission beyond oral-oral contact. 
 
Real-time PCR techniques have made it possible to estimate the EBV viral load 
in specific samples. The demonstration of high numbers of EBV in cervical 
secretions of some individuals has been interpreted as shedding of cell-free virus 
rather than a passive carrier state of lymphocytes (63). 
 
Correlation between the detection of EBV from the male urethra and 
microscopical urethritis was shown in paper III, but the causal connection with 
urethritis is still to be shown. Non-herpetic acute general ulcers in young women 
have been related to primary EBV infection and occasionally EBV has been 
isolated directly from the vulvar ulcer (72, 73). However, this type of acute 
genital ulcers associated with signs of systemic infection is not thought, by most 
authors, to be sexually transmitted. Whether such cases of acute vulvar ulcers 
reflect a primary genital EBV infection remains to be shown. 
 
Diagnostic methods 
EBV is detected in blood or cerebrospinal fluid by PCR methods in patients with 
severe infections. Acute EBV infection is diagnosed through demonstration of 
IgM antibodies. Heterogenetic antibodies that agglutinate erythrocytes 
(Monospot test), antibodies to viral capsid antigen (VCA), early antigen (EA) 
and Epstein-Barr nuclear antigen (EBNA) are serological analyses indicating 
different phases of EBV infection. 
 
Treatment 
There is no effective treatment in clinical practice. 
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Adenovirus 
Adenovirus (AV) belongs to the adenoviridae family and the name is derived 
from the “adenoidal tissues” (tonsils) in which it was first identified. It is a 
double-stranded DNA virus of medium size (60-90 nm) without an envelope. In 
humans more than 50 different serotypes have been identified (60). 
 
Epidemiology/clinical infections 
AV accounts for about 10 % of acute airway infections and is the second most 
frequent cause of gastroenteritis in children. The incubation time is about one 
week and lymphadenopathy is common (74). Adenoviral conjunctivitis with 
seasonal outbreaks is often seen. AV infections complicated with meningitis and 
encephalitis have been described (75, 76). Severe infections with AV are seen in 
immunocompromised individuals, especially children (44). 
 
Transmission 
The primary transmission route of respiratory AV infections is by circulating 
infected droplets, but virus particles are also excreted in stool. Eye infections are 
often contracted through bathing water or direct contact. Gastroenteritis is 
transmitted via the faecal-oral route. 
 
Adenovirus as an STI 
Adenovirus as a cause of non-gonococcal urethritis in men has been reported, 
often with simultaneous conjunctivitis or upper respiratory tract infection. 
Adenoviruses were detected in 12 men (4%) with NGU compared to one case 
(0.3%) in the control group without urethritis in a study by Bradshaw et al. in 
2006. The two symptoms, severe dysuria and meatitis, were both associated with 
detection of adenovirus in this study (77). 
Our knowledge of adenovirus as an STI in women is limited. Of 175 female 
patients in an STI clinic in Australia, none of the cervical samples were positive 
for adenoviruses (A to E) with a multiplex PCR method (78). Adenoviruses 
have only rarely been detected in the female genital tract (79). 
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Diagnostic methods 
Adenovirus can be detected by PCR assays, antigen detection or serologic 
methods. Antibody assays are utilised in respiratory infections but are not 
adequate for intestinal and eye infections. Quantitative PCR methods can be 
used to estimate the amount of virus in blood in immunocompromised children 
with suspected chronic AV infection. Although rarely used, virus isolation 
methods are still performed in some laboratories (44). 
 
Treatment 
There is no treatment available in clinical practice.  
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Bacterial agents 
 
Chlamydia trachomatis 
Chlamydia trachomatis is a small obligate intracellular organism, which is 
classified as a bacterium, although it cannot multiply outside the host cell. The 
serovars (genotypes) B-K produce genital infections, whereas A-C are the cause 
of trachoma. The main locus is columnar and transitional epithelium in the 
urogenital region, but C. trachomatis also infects squamous epithelial cells of 
the conjunctiva. 
 
Epidemiology 
C. trachomatis is the most common bacterial sexually transmitted infection 
world-wide. Incidence rates of genital chlamydia infection in the general 
population in Sweden are not known. The reported number of cases reflects the 
proportion of infected people in the tested populations and the extent of 
surveillance programs. In 1988 C. trachomatis was included in the Swedish 
Communicable Diseases Act. This implies that all diagnosed cases are reported, 
both from clinicians and laboratories. Patients with suspected or explicit C. 
trachomatis infection are given medical care and treatment free of charge, and 
partner tracing and notification are mandatory. Screening for genital chlamydia 
infection in Sweden started in the 1980s and the number of reported cases 
during the last decades is shown in Figure 3 (80). 
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Fig.3. The number of C. trachomatis cases reported to the Swedish Institute for 
Communicable Disease Control 1997-2010 (80) 
 
 
 
 
 
 
Men 
 
Women 
The number of C. trachomatis cases increased during the late 90s, reaching a 
maximum of 47000 in 2007. A false decline, due to a mutant strain of C. 
trachomatis not detected by some of the diagnostic tests, was noted in 2006 
(81). Of patients tested for chlamydia in STI clinics in Gothenburg 
approximately 10% were positive in 2007 (82). Among tested individuals in 
Sweden the male: female ratio is 1:3, i.e. the number of unrecorded cases may 
be higher among men. Population-based studies of the C. trachomatis 
prevalence in the US and sub-Saharan Africa indicate higher prevalences in 
women than men (83, 84). As for HIV and HSV-2, the transmission of C 
trachomatis may be more efficient from men to women than from women to 
men, attributed to the larger exposed mucosal area in women (1). Furthermore, 
the female genital mucosa is often exposed to semen for prolonged periods. The 
prevalence rate also depends on age, geographic location, sexual behaviour and 
diagnostic test methodology. 
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Clinical picture 
Clinical manifestations in men are urethritis and epididymitis and in women 
urethritis, cervicitis and pelvic inflammatory disease (PID). Notably, the 
majority of infected women and men are asymptomatic. In symptomatic males 
dysuria and urethral discharge are common. Some infected women suffer from 
abnormal vaginal discharge, intermenstrual vaginal bleeding or vaginal bleeding 
after intercourse but these symptoms are unspecific (85). 
 
Cases of chlamydia conjunctivitis in adults are seen occasionally. Rectal 
chlamydia infection is usually asymptomatic and mostly seen in MSM (86). C. 
trachomatis has been detected in the pharynx, but the clinical significance of 
oro-pharyngeal C. trachomatis is uncertain (87, 88). Occasional cases of 
sexually acquired reactive arthritis and Reiter’s syndrome following genital 
chlamydia infection are seen. 
 
The more invasive variant of C. trachomatis, subtype L, causing 
lymphogranuloma venereum, seems to be increasing among MSM in many 
European cities (89). 
 
The extent to which chlamydia is the cause of long-term complications like tubal 
factor infertility and ectopic pregnancy is being debated (90). Pelvic 
inflammatory disease (PID) is caused by chlamydia (and other bacteria) 
ascending from the vagina and cervix into the upper genital tract (the uterus, 
fallopian tubes and the peritoneal cavity). Symptoms of PID include vaginal 
discharge and bleeding, dyspareunia and abdominal pain. One of the problems 
in assessing the risk of long-term complications caused by C. trachomatis is the 
lack of established diagnostic criteria of PID. Infertility as a result of C. 
trachomatis in men has also been proposed (91). 
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Transmission 
Infection with C. trachomatis is mainly spread through sexual intercourse, but 
transmission in other intimate situations including transfer of genital secretions 
cannot be excluded. Transmission from mother to infant during labour can result 
in conjunctivitis and pneumonia in the newborn child. 
 
Diagnostic methods 
The development of diagnostic methods has yielded highly sensitive nucleic 
acid amplification tests (NAAT) for C. trachomatis as polymerase chain 
reaction (PCR) and strand displacement assays (SDA). These methods 
synthesize high amounts of DNA copies from bacterial chromosomal or plasmid 
DNA. In Sweden two PCR methods, Roche Diagnostics and Abbot 
Laboratories, and one SDA method, Becton Dickinson, are equally 
recommended.  
 
In male patients samples for the diagnosis of C. trachomatis are collected from 
the urethral orifice with a cotton swab or as first voided urine. In women 
diagnostic samples from the uterine cervix, the vagina, the urethra and first 
voided urine are used separately or in different combinations to increase the 
sensitivity of the test. The specificity is high irrespective of the source of the 
sample in both men and women. A report from the SBU ( Swedish Council on 
Health Technology Assessment) in 2010 demonstrated a higher sensitivity of 
vaginal samples than samples from other origins in women. The lowest 
sensitivity was shown for urine samples in women (92). On the contrary, first-
voided urine samples have a slightly higher sensitivity than urethral samples in 
males (93). Earlier used culture methods have mostly been replaced by NAAT, 
but are still performed in some laboratories. 
 
Treatment 
The recommended treatment in Sweden is tetracyclines for 9-10 days, i.e. 
doxycycline 100 mg twice a day the first day and then once daily for another 
eight days. An alternative regimen is a single dose of azithromycin (1g). 
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Mycoplasma genitalium 
Both mycoplasma and ureaplasma species belong to the class of bacteria called 
Mollicutes, which means “soft skin”. The mycoplasmas lack a cell wall and are 
surrounded by a cell membrane. Mycoplasma genitalium (Mg) has the smallest 
genome of all self-replicating microorganisms (94). Like C. trachomatis Mg is 
incapable of replication outside the host cell and has affinity for columnar and 
transitional epithelium in the urogenital region. 
 
Epidemiology 
The incidence of genital infections with M. genitalium in the general population 
is not known. Among STI patients in Sweden the reported frequency of Mg is 
3.5-7% in both sexes (95-97), in most studies about half as common as C. 
trachomatis. Bjartling et al. found a prevalence of Mg in 7598 female attendees 
in a gynaecology outpatient clinic of 2.1% (98). 
 
Clinical picture 
Mg is an etiological agent of male urethritis, both non-gonococcal urethritis 
(NGU) and non-chlamydial-non-gonococcal urethritis (NGNCU) (99). The role 
of Mg in prostatitis is a matter of debate, although a few small studies have 
found the organism in urine and semen of prostatitis patients (100, 101). Even 
less is known regarding Mg epididymitis. A case report of a male patient with 
concomitant unilateral conjunctivitis and urethritis with positive PCR for Mg 
from both locations has been published (102). The reported prevalence of Mg in 
rectal samples from 500 MSM in San Francisco was 5% (103). 
 
There are studies suggesting Mg as an etiological agent in mucopurulent 
cervicitis (104), in endometritis (105), in post-abortion PID (106) and in 
salpingitis (107), but additional work in this field is needed. 
 
Transmission 
M. genitalium has become established as an STI pathogen. Falk et al. detected 
Mg in a significantly higher proportion of male and female sexual partners to 
patients with Mg (108). 
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Diagnostic methods 
M. genitalium is detected by in-house PCR methods in first-void urine and 
samples from the urethra and/or the cervix. 
 
Treatment 
Recommended therapy is a 5-day regimen of azithromycin, with 500 mg the 
first day followed by 250 mg for another 4 days. Increasing resistance to this 
drug has been noted in some countries (109, 110). In cases of resistance to 
azithromycin, moxifloxacin, in oral doses of 400 mg once daily for 7-10 days, 
has proved to be highly effective (111). 
 
 
Ureaplasma urealyticum 
Ureaplasma urealyticum (Uu) was detected more than half a century ago (112) 
and has been demonstrated to be common in the genital tract of both men and 
women. It was shown to be associated with an increased number of sexual 
partners in a study from 1973 (113) and its significance in urethritis has been a 
matter of debate ever since (114-116). Some studies have shown association 
between Uu biovar 2 and urethritis in men (117, 118), but after multiple logistic 
regression Povlsen et al. only found independent correlation between Uu and 
age<=24 years but not between Uu and NGU. Uu as a sexually transmitted 
pathogen in women has not been fully investigated. It was detected in 3% of 
cervical samples from female STI patients in Australia (78) and its correlation to 
cervicitis is not known. In a study of male STI patients, Uu was detected in 30% 
of both men with and without NGU (117). 
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THE CONCEPTS OF URETHRITIS AND CERVICITIS 
 
Urethritis 
The term urethritis means inflammation of the urethra. Common symptoms are 
urethral discharge, pain during micturition and urethral pruritus or discomfort. A 
high proportion of men and women with urethritis are asymptomatic. Persistent 
or recurrent urethritis following treatment of acute non-gonococcal urethritis 
(NGU) occurs in 10-20% of male patients (119). 
 
Epidemiology 
Urethritis is the most common clinical syndrome in male patients in STI clinics. 
Our knowledge of the prevalence of urethritis in the general population is 
limited. In 2009 the prevalence of urethritis among 5447 young men aged 18-27 
years in the US was estimated; In this study 1.2% of the participants reported 
symptoms of urethritis (120). 
 
Microscopical urethritis 
Microscopically, urethritis is defined as an increased number of polymorph 
nuclear leukocytes (PMNL) in a Gram or methylene-blue stained smear from the 
distal part of the urethra. The most established definition of microscopic 
urethritis is ≥5 PMNL per high power field (HPF) in ≥5 fields in 1000x 
magnification (121).  
 
In men a PMNL count of ≥5 in a stained urethral smear has been correlated with 
detection of C. trachomatis. Among men with C. trachomatis infection 63-82% 
display this microscopic criterion of urethritis. Studies have shown that 94% of 
male patients with Ng and 77% of men with Mg have PMNL counts ≥5 in 
stained urethral smears (122, 123). 
 
The signs and symptoms of urethritis in women are less generally defined. 
However, in most instances, clinically and scientifically, the same definition as 
for men has been used. In a study by Falk et al. women with 5-9 PMNL per HPF 
in urethral Gram stain were categorized as “grey-zone-urethritis” (108). 
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Etiology 
Also the etiology of urethritis has mainly been investigated in male patients. 
Neisseria gonorrhoeae was the etiological pathogen first identified in male 
urethritis. Cases negative for Ng were defined as non-gonococcal urethritis 
(NGU). C.  trachomatis was discovered in the 1970s and is detected in 11-43% 
of patients with NGU. In recent years M. genitalium has been identified as a 
causal agent in 9-25% of NGU cases. Other reported agents in NGU are 
adenoviruses, T vaginalis and herpes simplex virus detected in 2-45, 1-20% and 
2-3%, respectively (124). EBV has been detected in urethral smears from men 
with N. gonorrhoeae (125). However, in 20-50% of patients with NGU no 
pathogen is isolated (1) and the diagnosis in such cases is “non-specific 
urethritis”. This diagnosis most probably includes both men with non-infectious 
urethritis and men infected with not yet identified pathogens. 
 
Partner tracing 
An evaluation of partner notification of men with asymptomatic NGNCU stated 
that female contacts with a high prevalence of C. trachomatis were identified, 
but at the cost of quite high resources (126). In another study only 1/41 (2.4%) 
female partners of men with asymptomatic NGNCU were diagnosed with C. 
trachomatis (127). There is also some concern that invasive urethral screening in 
STI clinics might reject asymptomatic men from attending. 
 
 
Cervicitis 
Cervicitis is the term for inflammation of the uterine cervix, but there is no 
widely accepted definition of this condition. The clinical signs mostly used for 
cervicitis are visible mucopurulent secretion and friability (easily induced 
bleeding) of the cervical portio. Various microscopical criteria have been used, 
such as >10 or >30 PMNL per HPF in a stained cervical smear (1). 
Inflammatory cells in a vaginal wet smear in 40x magnification have been 
interpreted as reflecting inflammation of the cervix with the limits 10 PMNL per 
HPF (128) or a ratio of PMNL:epithelial cells >1 judged as cervicitis (129). 
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AIMS OF THE STUDIES: 
 
 
 
I. To estimate the age-related seroprevalence of HSV-2 in male and female STI 
patients. To assess the proportion of symptomatic, unrecognised and true 
asymptomatic patients with HSV-2 infection, initially and after receiving the 
serological results and counselling 
 
II. To estimate the age-related seroprevalence of HSV-2 in pregnant women and 
compare with contemporary female STI patients 
 
III. To investigate the role of viral organisms in male urethritis 
 
IV. To investigate asymptomatic shedding from the uterine cervix of five human 
herpes viruses; cytomegalovirus (CMV), Epstein-Barr virus (EBV), herpes 
simplex virus (HSV) type 1 and type 2 and varicella zoster virus (VZV) in 
young women 
 
V. To estimate the association of the microscopical and clinical signs of 
inflammation routinely used in Scandinavian STI clinics with a positive test for 
C. trachomatis in female STI patients 
29 
MATERIALS AND METHODS 
 
The studies were conducted at the STI clinic of Sahlgrenska University Hospital 
(I, III, V), Gothenburg, at the STI clinics in Skövde and Borås (III) and at two 
Maternity Centers in Western Sweden: Västra Frölunda (II, IV) and Vänersborg 
(IV). The microbiological analyses were performed in the virological and 
bacteriological laboratories at the Department of Clinical Microbiology, both in 
Sahlgrenska University Hospital. 
 
Subjects and samples 
 
Paper I: Patients (first visitors) who attended the STI clinic of Sahlgrenska 
University Hospital during the recruitment period were asked to participate in 
the study. The catchment period ran from January 2000 to May 2001, except 
during three summer months in 2000 and some additional days, when the clinic 
was too busy. All included patients were given written information about the 
study and the natural course of genital herpes infections. Of 1769 patients 
invited to participate, 1014 (57%) agreed to be included. Demographics and data 
on sexual behaviour and previous STI are shown in paper I, Table I. The age and 
sex distribution was similar between the included patients and the ones 
declining, with a mean age of 30 years for the men and 28 years for the women. 
The motives for abstaining were not consecutively investigated, but among 53 
patients asked by a nurse common reasons were unwillingness to have a blood 
test or to know about a silent HSV-2 infection. One third did not want to tell the 
reason. 
 
Paper II: In paper II the HSV-2 seroprevalence in pregnant women was 
investigated. Sera were collected from women attending an antenatal clinic in 
Western Sweden during 2002. As is routine in Sweden blood was drawn for 
serological analyses of HIV and rubella from all the 661 women who attended. 
A random sample of 299 sera from these 661 frozen blood samples was selected 
and tested anonymously for HSV-2 antibodies. The mean age of the pregnant 
women was 30.5 years (range 17-45 years). 
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 For comparison 290 female STI patients, included in the STI patient population 
in paper I, were separately analysed.  
 
Paper III: Male attendees at the STI clinics of Sahlgrenska University Hospital, 
Södra Älvsborgs Hospital and Skövde Hospital were included from 2004 to 
2007. Patients were not included when the clinics were too busy. The inclusion 
criterion was more than four PMNL per HPF in the urethral smear in at least 
five HPF. Initially 124 men met this criterion. Since 12 samples were lost in the 
laboratory, 112 patients with urethritis were analysed. 100 of these were 
included in the STI clinic at Sahlgrenska University Hospital. As controls, 103 
male patients, who attended the STI clinics for other reasons than urethritis and 
had 0-2 PMNL per high power field in their urethral smears, were included. 
None of the control patients had symptoms of urethritis. None of the included 
men had visual lesions of genital herpes or balanitis involving meatus. 
Demographic data for patients with microscopic urethritis and for the controls 
are shown in paper III, Table 1. The median age was 28 years in the group with 
urethritis and 30 years in the control group. The number of partners during the 
last six months was similar between the groups, but a history of STI was more 
common among the patients with urethritis. 
 
Collection of smears for microscopy 
The samples for microscopy were collected with a plastic loop of 1 μl from the 
distal part of the urethra. The methylene-blue smear was then examined by light 
microscopy at magnification x1000. The used definition of microscopical 
urethritis was ≥5 PMNL per high power field in ≥5 fields. Specimens for 
virological analyses were collected with a thin cotton-tipped swab from the 
distal urethra and put in a tube with 1 ml of sterile NaCl. First-voided urine 
samples were collected for detection of Chlamydia trachomatis, Mycoplasma 
genitalium and Ureaplasma urealyticum. For all patients the time since last 
micturition was >1 hour.  
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Paper IV: 305 young Swedish women, who attended two Maternity Centers in 
Western Sweden, were included. The enrolment periods ran from October 2004 
to May 2005 and November 2005 to April 2006. All women, who were invited 
to the population based Cervical Cancer Screening Programme at the age of 23 
and 26 years and attended during these periods were included. Cervical 
specimens were obtained by putting the cytobrush used for Pap smear in a tube 
with 1 ml ethanol (95%). The tubes were then stored at 8°C until analyzed. The 
samples were marked with the name of the study but with no patient 
identification. 
 
Paper V: Ninety-nine female patients, who attended the STI clinic of 
Sahlgrenska University Hospital due to chlamydia partner notification from 
February 2005 to October 2007, were included. In Sweden, according to the 
Communicable Diseases Act, all cases of chlamydia infection are reported and 
partner tracing is mandatory. 
 
A genital examination was performed on all patients and the cervix was initially 
cleaned of excess mucus with a large cotton swab. Samples for microscopy were 
collected before the specimens for C. trachomatis SDA in all cases. Time from 
the latest micturition was > one hour for all patients. 
 
Collection of samples for detection of Chlamydia trachomatis 
The specimens for detection of Chlamydia trachomatis were sampled by 
separate standard cotton swabs from the cervix and the distal urethra after the 
smear from each site. Both swabs were put in the same tube with BD ProbeTec 
ET transport medium, which was sent to the Department of Bacteriology, 
Sahlgrenska University Hospital the same day. 
 
Collection of smears for microscopy 
From endocervix a sample was taken by a cotton swab and from urethra by a 
plastic loop of 1 µl; these specimens were stained with methylene blue and 
visually examined through a light microscope (x1000). 
For wet smear examination samples were taken from the vaginal wall by a 
plastic loop and diluted in 10% KOH and 0.9% NaCl, respectively. The wet 
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smear was examined with a phase contrast microscope (x400). In addition to 
recording the number of PMNL in relation to epithelial cells the presence of clue 
cells, amine odour and signs of candidiasis were noted. 
 
 
Laboratory methods / Diagnostic methods  
 
Paper I: Antibodies for HSV-2 were determined by an ELISA test using a Helix 
pomatia lectin-purified glycoprotein G2 antigen (gG-2) described by 
Svennerholm et al. (130). A high titrating HSV-1 positive serum was used as 
control and the cut-off was set to the mean value of this control plus 0.2 
absorbance units. Positive sera were further analysed by the ELISA test 
Gull/Meridian. Sera with discordant results between the two ELISA tests were 
confirmed by a Western blot assay previously characterised in the Virological 
Laboratory at Sahlgrenska University Hospital and considered as gold standard 
at that time (131). Virus isolation and typing of HSV were performed as 
previously described (132). The PCR assay for detection of HSV was based on 
primers from the type-unique promoter region of the glycoprotein D gene (133). 
 
Paper II: Sera were initially tested by the in-house ELISA test based on the 
helix pomatia lectin-purified gG-2 antigen described for paper I (above). For 
verification, all positive sera, both from the pregnant women and from female 
STI patients, were confirmed by a commercial test approved by the US Food 
and Drug Administration: HerpeSelect HSV-2 ELISA (Focus Diagnostics), 
which is based on recombinantly produced gG-2. When making a comparison 
with older studies the results of the in-house gG-2 ELISA without further 
confirmation were used. 
 
Paper III: Real-time PCR (TaqMan, Applied Biosystems, Foster City, CA, 
USA) was used for the detection and quantification of DNA of EBV, CMV, 
HSV-1, HSV-2 and adenovirus as well as ß-globin and PhHV-1 DNA. The 
specific methods for detection of each of these viruses have been described 
previously (134-137). As internal controls, to assess an efficient extraction of 
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DNA, PhHV-1 primers and probe were used as earlier reported by Niesters 
(138). The method for analysis of human ß-globin, used to guarantee a sufficient 
amount of DNA in the samples, was published in 2001 (139). 
Chlamydia trachomatis was detected by the DNA amplification technique strand 
displacement amplification (SDA) using BD ProbeTec ET System C. 
trachomatis amplified DNA assay (Becton Dickinson Diagnostic Systems) 
(140). This assay amplifies a single target region in the C. trachomatis 
chromosomal CDA cryptic plasmid and detects both the C. trachomatis wild-
type and the mutant strain described in 2006 (81). This method is used as the 
standard method for detection of C. trachomatis in the laboratory of 
Microbiology, Sahlgrenska University Hospital.  
PCR identifications of Mycoplasma genitalium and Ureaplasma urealyticum 
were made as previously described (141, 142). 
 
Paper IV: PCR detection and quantification of EBV, CMV, HSV-1 and HSV-2 
and VZV were made by a quantitative real-time (TaqMan) PCR assay as 
described in paper III. Analyses of ß-globin and PhHV-1 were performed as in 
paper III. 
 
Paper V: NAAT detection of C. trachomatis (Becton Dickinson) was performed 
as described in paper III (samples from the uterine cervix and the urethra in 
paper V). This assay also detects the mutant strain of C. trachomatis described 
in 2006. 
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Statistical analysis 
 
Paper I: Statistical calculations were performed in the Epi Info program. 
Differences of proportions were compared using the Chi-squared test with the 
level of significance set to 5%. 
 
Paper II: Point estimates of proportions were given with 95% CI. When 
comparing the HSV-2 seroprevalence of the pregnant women in paper II with a 
previous study population in Malmö 1990-93 our population was age-adjusted to 
the age distribution of the Malmö cohort. 
 
Paper III: Fisher’s exact test was used to compare clinical and laboratory data 
between patients and controls. Possible confounding factors, including co-
variations of pathogens, were investigated by multivariate logistic regression. In 
the multivariate analysis the included variables were “chlamydia infection”, 
since it was found to be significant in the univariate analysis and “previous 
chlamydia infection”, a factor shown to be associated with urethritis in the 
literature and also significant in the univariate analysis of paper III. 
 
Paper IV: Point estimates of proportions were given with 95% CI. 
 
Paper V: Fisher’s exact test was used for univariate associations. Statistical 
significance was set to p<0.05. 
 
 
Ethical approval 
 
The studies I-III and V were approved by the Ethics Committee of the Medical 
Faculty at the University of Gothenburg. For paper IV ethical approval was not 
needed, since the study did not include any patient-identifiable data or samples 
and all samples were destroyed at the end of the study. 
35 
SUMMARY OF THE RESULTS AND DISCUSSION 
 
Seroprevalence of herpes simplex type 2 (Papers I-II) 
 
Serological tests discriminating herpes simplex type 2 from type 1 have made it 
possible to study the specific prevalence of HSV-2 in different populations and 
to follow changes in the epidemiology of HSV-2 infections. Serological 
evidence of HSV-2 is a marker of genitally acquired infection and HSV-2 
prevalence is negligible in individuals who have never been sexually active. 
In papers I and II the seroprevalence of HSV-2 in two different populations has 
been studied: STI patients (first visitors) of both sexes in our STI clinic 2000-
2001 and pregnant women at their first visit in an antenatal clinic in Gothenburg 
in 2002.  
 
Among 1014 STI patients giving a blood test for detection of HSV-2 antibodies, 
152 (15%) were seropositive: 12% (86/724) of the male patients and 23% 
(66/290) of the females. Comparison between studies is difficult due to 
differences in both diagnostic methods and the studied populations; e.g. patients 
with symptoms of and/or history of genital herpes are included by some authors 
and excluded by others. Moreover, since HSV-2 seroprevalence is related to sex, 
age and ethnical background, accurate information about the studied population 
is essential (143). Reported figures on HSV-2 seroprevalence in STI patients 
from France 1994, Italy 1997-98, Spain 1996-97 and the UK 1992 were for 
females/males 67/45%, 25/25%, 30/12% and 25/17%., respectively * (144). 
 
Of the pregnant women 10.4% (31/299) were seropositive in the type-specific 
in-house HSV-2 ELISA. Of these, 27/31 were verified as positive in the HSV-2 
Focus test. Hence, the resulting seroprevalence of HSV-2 was 9.0% (27/299), 
which was at a level similar to contemporary studies of pregnant women from 
Norway and Finland (145, 146). 
 
* References of seroprevalence in different populations have been selected among those 
which report separate figures for gender and age groups and with a sample size of >100. 
Studies of HIV positive populations and MSM populations have been excluded, since they are 
not relevant for comparison in this context.  
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During the 1980s high figures on the seroprevalence of HSV-2 in pregnant 
women were reported from Stockholm and Malmö (Table II, paper II). These 
high prevalences of HSV-2 antibodies, >30% in most age groups, were 
considerably higher than reported from other northern European countries 
around the same period of time. The reported HSV-2 seroprevalences in 
Germany, Finland and Norway were 8.9%, 16% and 27%, respectively (147-
149). 
Epidemiological data on time trends of HSV-2 seroprevalence are limited. A 
population-based cross-sectional study from the US demonstrated a significant 
decrease from 21% in 1988-1994 to 17% in 1999-2004 (150). However, a cross-
sectional study from Sweden found no significant change in HSV-2 
seroprevalence during the first six years of the 1990s (151). Comparison of the 
pregnant women described in paper II with the latest cohort studied by Persson 
et al. from Malmö (152) showed a significant decrease in HSV-2 seroprevalence 
from 20.7% in 1990-93 to 9.4% in 2002 (after age-adjusting the population from 
Gothenburg to the age distribution of the Malmö cohort). 
 
The comparison of HSV-2 seroprevalence with female STI patients in paper II 
showed, as expected, a much higher frequency of HSV-2 antibodies in this 
population. This illustrates the importance of distinct report of patient selection. 
Although these two populations were of female gender and from the same part 
of Sweden, a high-risk sexual behaviour is more common in STI patient 
populations and is mirrored by a higher seroprevalence of HSV-2. 
 
In papers I and II sera were initially tested by the in-house ELISA test based on 
the helix pomatia lectin-purified gG-2 antigen. In paper I positive sera were 
further analysed by the ELISA test Gull/Meridian. Sera with discordant results 
between the two ELISA tests were confirmed by a Western blot assay. In paper 
II positive results of the in-house gG-2 test were confirmed by HerpeSelect 
HSV-2 ELISA/Focus Diagnostics, since the Gull/Meridian ELISA test, used for 
confirmation in paper I, was no longer available. Both the commercial Focus 
ELISA and the in-house gG-2 assay have a high reported sensitivity and 
specificity in high-prevalence populations (5, 153). Also the Gull/Meridian 
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ELISA test was approved by the FDA and had a high reported sensitivity and 
specificity (154). 
The use of gG-2-based assays in populations with a low prevalence of HSV-2 is 
more controversial. In a study from 2002 the authors stated that only initial 
testing by a gG-2 ELISA confirmed by Western blot testing of the positive 
results would give a PPV over 80% in a population with a HSV-2 
seroprevalence of 10% (155). Western blot is the diagnostic gold standard 
according to the 2010 European guidelines for the management of genital 
herpes, but the method is labour-intensive and not available in most clinical 
settings. Results of Western blot can be difficult to interpret as illustrated by a 
recent study from Canada: Of 364 tested sera, 14 (3.8%) had to be excluded due 
to inconclusive results of the Western blot (153). Golden et al. demonstrated a 
higher risk of false positive results of HSV-2 ELISA tests in HSV-1 seropositive 
individuals (156) and it is recommended to confirm positive HSV-2 ELISA tests 
with an additional unrelated test, especially when the positive results are in the 
low-titer range. 
 
When commercial type-specific serological tests became available, there was a 
debate concerning screening for HSV-2 infection in high-risk populations such 
as STI patients, MSM and HIV positive individuals. The motives for screening 
were that diagnosing asymptomatic and unrecognised HSV-2 positive patients in 
high-risk settings should allow these individuals to practise safer sex and 
thereby prevent further transmission of HSV-2 (157). It has also been stated that 
STI patients seeking medical care should have the right to be tested for a 
sexually transmissible infection such as HSV-2. Against screening for HSV-2 in 
STI clinics stands the knowledge that a positive serological result of HSV-2 
might have negative psychosocial and psychosexual consequences, especially 
for vulnerable individuals (158). On the other hand, other studies have reported 
no apparent psychosocial impact of diagnosing subclinical HSV-2 infection 
serologically in STI patients (158, 159). The ethical considerations regarding 
serotesting of HSV-2 were discussed by Krantz and Löwhagen in 2004 (160). 
Their conclusion was that a correct diagnosis provides ethical benefits for 
38 
patients with symptoms. For asymptomatic individuals, however, the 
disadvantages may outweigh the advantages. 
 
Health economy consequences are to be considered as well. A study estimating 
the costs and benefits of screening heterosexual couples for asymptomatic 
infection with HSV-2 estimated that screening could prevent a new case of 
HSV-2 infection at a cost of 8000-9000 USD. The authors stated that screening 
would result in a decrease in the incidence of HSV-2 infections and an increase 
in health care costs. Whether this cost-benefit analysis would justify HSV-2 
screening compared to other preventative health interventions was uncertain, 
since the impact of HSV-2 infection on quality of life has not been sufficiently 
studied (161). Another problem is that the results of serological tests are difficult 
to interpret due to varying time to seroconversion and demonstrated fluctuation 
in estimated antibody levels over time in patients with established HSV-2 
infections (162). 
 
Serological HSV-2 screening of STI patients or other high-risk groups is no 
longer recommended. Remaining clinical indications for HSV-2 antibody testing 
are recurring genital symptoms, including those typical of clinical herpes, and 
atypical lesions like fissures, when PCR tests have been negative. As described 
by Löwhagen et al., serological testing to distinguish between recently acquired 
HSV-2 infections and clinical recurrences of former asymptomatic infections 
might be useful in selected patients (14). Whether partners of patients with 
genital herpes should be tested for HSV antibodies will have to be decided from 
case to case. 
 
Routine serological testing of pregnant women for HSV-2 has been discussed 
and advocated especially in the US (163). Considering the low prevalence of 
HSV-2 in pregnant women, the PPV of a serological test will be low. 
Furthermore, to identify the women at highest risk, the male partners have to be 
tested as well, in order to find HSV serodiscordant couples with women 
susceptible for and exposed to HSV. A health economy study of screening 
pregnant women and their partners for HSV estimated a resulting decrease in 
HSV-1 and HSV-2 infections in women and infants and a save of costs (164). 
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Acceptance of herpes simplex type 2 antibody testing (Paper I) 
 
Patients (first visitors) of both sexes attending the STI clinic at Sahlgrenska 
University Hospital were offered a blood test for detection of HSV-2 antibodies. 
Of 1769 patients asked to participate, 1014 (57%) agreed to be included. Age 
and sex did not differ between those who chose to be tested and those who 
abstained. The participation rate in similar studies from STI clinics in Seattle 
and the UK were 52% and 90%, respectively (165, 166). 
 
Acceptance of HSV-2 antibody testing has been shown to be independently 
correlated to female sex, older age, a history of STI, perceived vulnerability to 
HSV-2 infection and the test being free of charge (165, 167). The acceptance of 
HSV-2 antibody testing is higher among patients in STI clinics than in general 
medical clinics. In a study from Leeds to assess patients’ attitudes toward HSV-
2 antibody testing and the effect of written information regarding genital herpes, 
200 clinic attenders were randomly divided into two groups; Half of the patients 
were given a detailed three-page sheet of information on genital herpes, and the 
others were simply asked to fill in a questionnaire and give a blood sample for 
HSV-2 antibodies without additional information. The authors could not 
demonstrate any differences between the groups in the willingness to perform a 
blood test for HSV-2 antibodies, and the overall refusal rate for testing was only 
2% (166). 
 
There is reason to believe that patients’ willingness to be tested is affected by 
what aspects of HSV-2 infection are emphasised in written and oral information. 
In the work by Mullan et al. only 41% of the males and 37% of the females 
chose to be tested, and in that study the information stressed the disadvantages 
of performing the test (168). The relatively low participation rate in our study, 
compared to the one from Leeds, is probably due to the fact, that all clinicians 
involved in our study were observant of patients’ reluctance to be tested and 
scrupulous about not trying to persuade anyone. The tendency to abstain from 
HSV-2 antibody testing might be correlated to certain personality traits. These 
might co-vary with sexual risk-taking behaviour. However, this possible 
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personality type selection bias could not be avoided without the risk of causing 
psychological and psychosexual morbidity in sensitive patients. 
 
In the present study, drop-outs were not consistently asked about their reasons to 
abstain from serological testing. However, of 53 patients asked by the nurse why 
they did not want to participate: 34% gave the answer “don’t like blood tests”, 
17% of the drop-outs did not want to know about a possible silent HSV-2 
infection and one third of the patients did not want to tell their reason for not 
participating. Fear of needles is a logical reason to avoid a blood test and has 
been associated with abstaining in other studies (167). In paper I this is 
illustrated by a significant difference in the proportion of patients having an HIV 
test; 85% of the patients tested for HSV-2 compared to 36% of the ones 
abstaining. In some cases, recent high-risk sexual behaviour in combination with 
the knowledge that an HIV test should be postponed to be reliable, might have 
been the cause for abstaining. 
 
Demographics and data of sexual behaviour and STI of included patients and 
drop-outs are shown in Table I, paper I. A higher proportion of included patients 
had a history of genital herpes: 9% compared to 4% of the drop-outs. It is not 
surprising that individuals with experience of symptoms consistent with GH are 
more inclined to have a serological test for HSV than other patients. However, 
the proportion of patients tested for C. trachomatis and N.gonorrhoeae was 
significantly higher in the group not tested for HSV-2 antibodies and so was the 
occurrence of positive tests for these bacterial STI. Since there is co-variation 
between the prevalence of HSV-2 and other STI, this might, to some extent, 
compensate for the bias of the higher number of patients with symptomatic 
genital herpes in the study population. Data on the number of sexual partners 
and condom use did not differ between the patients tested for HSV-2 antibodies 
and the drop-outs. 
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Recognised and unrecognised infections with herpes simplex type 2  
(Paper I) 
 
Among 1014 patients giving a blood test for detection of HSV-2 antibodies 152 
(15%) were seropositive: 12% of the male patients and 23% of the females. 
According to the questionnaire, 62 (41%) of the seropositive patients answered 
that they had a history of genital herpes. The proportion of symptomatic 
infections among HSV-2 seropositive individuals varies between studies (28, 
169-172). In general, higher figures have been shown in STI clinics than in 
antenatal clinics or among blood donors (28). This could be explained by the 
fact that individuals with symptoms of genital herpes seek medical care in STI 
clinics. Moreover, as shown in the present study, patients with symptomatic 
genital herpes are more inclined to have a serological test for HSV-2 than more 
unselected populations. 
 
Twelve seropositive patients without a known history of genital herpes 
presented with symptoms and signs typical of genital herpes at the initial visit. 
In seven of these patients HSV-2 was detected, by PCR or culture, and no 
further follow-up was performed within the study. 
 
Of 83 seropositive patients without a documented history of genital herpes 
invited to a counselling visit, 65 (78%) showed up. Interviews with these 
patients revealed that 20/65 (31%) of the patients had had symptoms compatible 
with genital herpes defined as “recurring vesicles and/or ulcers in the genito-
anal region”. This group of patients illustrates the definition of “unrecognised 
infections”. Six patients with most of their recurrences in the peri-anal or gluteal 
region had not realised that it could be genital herpes, due to the localisation. 
After counselling, some of the patients admitted that they had had a slight 
suspicion of genital herpes, which they had tried to suppress. 
 
Uncharacteristic genital symptoms with low suspicion of herpes, such as periods 
of itching, eczema, balanitis and urethritis were reported by 11/65 patients. 
 
Fifty-two percent (34/65) of the patients attending for a counselling visit had not 
had any genital symptoms. 
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 A similar study of recognised and unrecognised HSV-2 infections showed that, 
after receiving a positive result of HSV-2 antibodies and counselling, 
approximately 50% of women with reported asymptomatic HSV-2 infection 
declared symptoms of GH (29). This illustrates the importance of HSV-2 
serological testing and information to help patients recognising clinical 
recurrences of HSV in order to practise preventive measures. 
 
The proportion of “unrecognised symptomatic infections” is related to the extent 
and contents of the given oral and written information preceding the question 
“do you have genital herpes”. If the patients in the present study had received 
the information and counselling given during the counselling visit at the initial 
visit before answering the questionnaire, some of those might have been put in 
the group with previous history of genital herpes. However, the most important 
factor for recognition of previously unspecific genital symptoms as 
manifestations of genital herpes is most probably the positive result of HSV-2 
antibodies. 
 
Asymptomatic HSV-2 seropositive patients had a history of genital candida 
more often than HSV-2 seronegative patients (42% vs. 26%). A similar result 
was seen in a study of pregnant women in 1993 (173). To a question about 
sensitive skin defined as tendency to redness, itching and pain after friction 
and/or washing, 45 % of the asymptomatic patients with HSV-2 antibodies 
answered yes compared to 28% of HSV-2 seronegative patients. These answers 
could represent atypical manifestations of genital herpes (i.e. unrecognised 
recurrences), but could also be due to a more vulnerable skin barrier 
predisposing both for non-specific irritative symptoms, HSV infection and 
candida. However, there was no difference in the occurrence of genital eczema 
between asymptomatic seropositive and seronegative patients.  
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Urethritis in men (Paper III) 
 
Signs or symptoms of urethral inflammation are common in male STI patients. 
However, the etiology is unknown in the majority of cases. In paper III 112 male 
patients with microscopical urethritis, defined as ≥5 PMNL per HPF, were 
tested for C. trachomatis, M. genitalium, U. urealyticum, HSV-1, HSV-2, CMV; 
EBV and adenovirus. For comparison, 103 male patients, who attended for other 
reasons than urethritis, with a maximum of 2 PMNL per HPF were included. 
None of the control patients had symptoms consistent with urethritis, whereas 
98/112 (88%) of the patients with microscopical urethritis reported discharge 
and/or dysuria. 
 
EBV was detected in 24/112 (21%) patients with urethritis compared with 6/103 
(6%) in the control group. This correlation between EBV and microscopical 
urethritis was statistically significant (p<0.01). None of the viruses, HSV-1, 
HSV-2, CMV and adenovirus, were found in the urethritis patients and therefore 
these analyses were not performed in the control group. As expected, a 
significant correlation was demonstrated for C. trachomatis, an established 
pathogen in urethritis; 17/112 (15%) compared to 3/103 (3%) in the controls. M. 
genitalium was detected in 7/112 (6%) of the urethritis patients compared to 
1/103 (1%) of the controls. This difference was not significant (p=0.067), 
probably due to the low prevalence in the urethritis group and to a relatively 
small sample size. U urealyticum was found in 10% of the patients in both 
groups. Uu subtype determination showed a similar distribution in patients with 
urethritis and controls. 
 
Our inclusion criterion of ≥5 PMNL per HPF in urethral smear was chosen to 
study male patients with “microscopical urethritis”. We regarded this method of 
diagnosis of urethritis as more objective and unbiased than including patients 
with symptoms of urethritis. The control group consisted of patients with 
confirmed absence of urethral inflammation estimated by a maximum of 2 
PMNL per HPF in the urethral smear. A control group as well defined as in 
paper III is hard to obtain, since sampling from the urethral orifice is feared by 
many patients. 
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At the time of inclusion of patients in the study of urethritis, all male STI 
patients were offered an evaluation of a urethral smear as part of the clinical 
examination and very few patients abstained. 
 
The limit of ≤2 PMNL per HPF in the control group was set to exclude patients 
with borderline urethritis, since it has been shown that intra- and inter-observer 
variation in the interpretation of smears is quite high. The reason for excluding 
men with balanitis involving meatus was to make sure that the observed PMNL 
originated from “true” urethral inflammation rather than from inflammation of 
the terminal urethra concomitant with balanitis. 
 
In previous studies of male urethritis, the inclusion criteria of patients and 
controls and the used diagnostic methods vary, making direct comparison 
difficult. In a comprehensive case-control study of urethritis by Bradshaw et al., 
329 symptomatic men were compared with 307 men without symptoms of 
urethritis regardless of microscopic evidence of urethral inflammation. As in our 
study (paper III) men with visual lesions of genital herpes were excluded, but 
meatitis, defined as “meatal inflammation and/or oedema” was noted in 38% of 
the patients with urethritis (sic!). First-stream urine was tested by SDA or PCR 
for C. trachomatis, M. genitalium, HSV-1 and -2, T. vaginalis, and 
adenoviruses. A significant correlation to urethritis was demonstrated for C. 
trachomatis, M. genitalium, adenoviruses and HSV-1, which were found in 
20%, 9%, 4% and 2% of the cases, respectively (77). 
 
The negative results of HSV and adenovirus in paper III could partly be 
explained by the exclusion of meatitis, which has been correlated with detection 
of these viruses in other studies (77). Regrettably, no analysis of drop-outs was 
carried out in our study of urethritis, but to our knowledge very few patients 
were excluded due to meatitis. In the above-mentioned study by Bradshaw et al., 
adenoviruses and HSV-1 were associated with sex with men and only one of the 
included urethritis patients in paper III defined himself as MSM. It is also 
possible that a microscopic inclusion criterion of presence of monocytes rather 
than PMNL would be more sensitive for viral infections. 
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The correlation between EBV and male urethritis has not been demonstrated 
earlier. Quantitative real-time PCR analysis of the 24 samples positive for EBV 
showed viral loads from 133 to 11500 copies/mL with a mean of 1343 
copies/mL. The number of viral copies was not higher in the 15 EBV positive 
patients with >10 PMNL per HPF than in the 9 patients with 5-9 PMNL per 
HPF, a finding that somewhat supports EBV as a pathogen in urethritis rather 
than a passive passenger in lymphocytes. Moreover, although EBV was found in 
10 patients with concomitant C. trachomatis, logistic regression analysis 
demonstrated an independent correlation between EBV and urethritis, unrelated 
to both actual and previous chlamydia infection. 
 
A study of male STI patients from 1975 detected HSV by virus isolation in 
1/114 men with urethritis, 1/61 without urethritis and 3/53 men with 
gonorrhoeae* (174). An Israeli study from 2003 identified HSV by antigen 
detection of urethral samples in 7/238 (2.9%) men with urethritis (175). A 
Swedish study of male patients also demonstrated HSV by virus isolation in 
7/688 (1.0%) male first visitors in an STI clinic in Stockholm* (176). However, 
it is difficult to interpret whether such low figures represent asymptomatic 
shedding of HSV unrelated to urethritis or, in fact, rare cases of HSV urethritis. 
 
To our knowledge, PCR detection of CMV from urethral samples in men with 
urethritis has not been published. In 1978 a study of 107 men with urethritis 
could not demonstrate CMV by virus isolation in any of the cases (121).  
 
When it comes to bacterial etiology of urethritis, C. trachomatis has been 
reported to account for 30-50% of the cases and M. genitalium for 10-30% (77). 
The relatively low prevalence of C. trachomatis and M. genitalium in the men 
with urethritis in paper III, 15 and 6%, respectively, was somewhat unexpected. 
One explanation could be that 26% of the patients with urethritis had received 
antibiotic treatment in the last three months. In a previous study from our clinic 
comprising 115 men with urethritis, the detection rates of C. trachomatis and M. 
genitalium were 36 and 14%, respectively (95). In this former study from 2000, 
antibiotic treatment during the last three months was an exclusion criterion. 
However, the low detection rate of M. genitalium in paper III could not be fully 
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explained by antibacterial medication, since the vast majority of the recently 
treated patients in that study had received tetracyclines, drugs which do not 
eradicate M. genitalium in most cases. A more likely reason is that the high 
proportion of patients with previous episodes of urethritis (63%) reflects the 
fact, that most patients were included during booked consulting hours rather 
than in the walk-in STI clinic, which has been increasingly busy in recent years. 
There is reason to believe that the prevalence of pathogen-positive urethritis is 
higher in patients seeking instant medical care than in patients accepting a 
booked appointment later on. 
 
U urealyticum biovar 2 has been correlated to urethritis in some studies, whereas 
other authors did not find any association, and the role of U urealyticum biovar 
2 in urethritis is still uncertain (77, 114, 117, 118). Although the detection of U. 
urealyticum in the male urethra has been correlated to the number of sexual 
partners (177), it is not known whether this represents colonisation or infection 
by U. urealyticum. 
 
The PCR assays utilised to analyse the prevalence of the different herpes viruses 
and adenovirus are highly sensitive and specific. Although not accredited for 
analyses of urethral specimens, all samples tested for ß-globin and phocid herpes 
virus type 1 were positive, showing that human DNA was amplified and that the 
DNA extraction procedure was efficient. 
 
The utilised diagnostic NAAT methods for C. trachomatis and M. genitalium 
are the ones used in clinical practice and shown to be both sensitive and specific. 
Analysis of first-void urine samples has proved to be more sensitive than 
urethral swab specimens in detecting both chlamydia and mycoplasma in male 
patients (93). The incubation time was > one hour in all patients in paper III, but 
a study from 2009 demonstrated that shortening the incubation time to 20 
minutes did not reduce the reliability of highly sensitive NAATs for C. 
trachomatis (178). 
 
* After exclusion of patients with external genital herpes lesions 
47 
Asymptomatic genital shedding of herpes viruses in young women 
(Paper IV) 
 
Viral DNA was detected in 66 (21.6%) of the cervical samples. The most 
common findings were CMV DNA, detected in 35 (11.5%) and EBV DNA 
found in 32 (10.5%) of the women. These two herpes viruses are widely spread 
in the general population with reported seroprevalence figures of 60-90% for 
CMV (179) and above 90% for EBV (180). HSV-1 DNA was detected in 5 
(1.7%) and HSV-2 DNA in 4 (1.4%) of the cervical specimens. Corresponding 
seroprevalence rates in young women were 60% for HSV-1 and 15% for HSV-2 
in 1990 (5). VZV DNA was not detectable in any of the specimens from the 
uterine cervix despite a seroprevalence of >95% in most European countries 
(181). The absence of VZV shedding was not surprising, since VZV has the 
least ability to reactivate of all herpes viruses. 
 
The estimated DNA level for the detected viruses was similar with a mean DNA 
quantity of 2.6 log genome equivalents (GE)/mL for CMV (range 1.7-4.3), 2.5 
log GE/mL for EBV (range 1.7-4.7 ), 2.4 log GE/mL for HSV-1 (range 1.7-3.5) 
and 2.6 log GE/mL for HSV-2 (range 1.7-4.1). The simultaneous presence of 
DNA from two or more herpes viruses was detected in 8 specimens. The 
simultaneous presence of two DNA viruses; CMV/EBV, HSV-1 /HSV-2 and 
CMV/HSV-2, was detected in 5 (1.6 %), 1 (0.3%) and 1 (0.3%) specimens, 
respectively. One woman had four detectable viruses (CMV, EBV, HSV-1 and 
2). The DNA viral loads within the CMV group were evenly distributed, 
whereas in a few samples of EBV and HSV a higher number of viral DNA 
copies were detected (Fig.1, paper IV). High viral loads may indicate a higher 
risk of transmission, both to a child during pregnancy and delivery and to a 
sexual partner. However, the amount of HSV or other herpes viruses required 
for sexual or perinatal transmission is not known (2). 
 
CMV DNA was detected in 11.2% of the cervical specimens, which is in 
accordance with previous studies. In the US cervical secretion of CMV was 
found in 13.6% of female STI patients (55); i.e. a population with an expected 
higher prevalence of pathogens associated with sexual behaviour. A study from 
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Italy demonstrated CMV DNA in 21% of cervical specimens from healthy 
women (17-25 years) with secretion rates decreasing with age (182). 
 
EBV DNA was detected in the uterine cervix in 10.5% of the women. In a 
previous Swedish study EBV was found in 8.9% (10/112) of the cervical 
samples in female STI patients (183), while an earlier investigation from our 
STI clinic demonstrated EBV cervical shedding in 38% of 91 female patients 
(184). From Italy the reported occurrence of EBV DNA in the uterine cervix of 
healthy women between 17 and 70 years of age was 18-19% and similar in all 
age groups (182). 
 
HSV-1 DNA was found in 5 (1.7%) and HSV-2 DNA in 4 (1.4%) of the cervical 
samples, respectively. Genital shedding of HSV is known to be intermittent and 
more frequent in HSV-2 than in HSV-1 GH. In a study by Koelle et al. cervical 
or external genital shedding during the first year after primary genital infection 
was detected in 1.25% of all days for HSV-1 and 4.3% for HSV-2 (185). The 
relatively high proportion of genital HSV-1 compared to HSV-2 in the cervical 
samples in the present study might be explained by the fact that HSV-1 has been 
shown to cause about 80% of first episodes of GH in young women (14). 
 
PCR analysis of cervical shedding of VZV, a virus with a seroprevalence at a 
level similar to EBV, >90% in the adult population, has, to our knowledge, not 
been published earlier. The demonstrated absence of VZV in the present study 
argues against general shedding of herpes viruses in the cervix. 
 
The seroprevalence of CMV, EBV, HSV-1 and HSV-2 is related to socio-
economic status. These viruses spread by close contact while VZV, which is not 
correlated to socio-economic factors, spreads mainly by the much quicker 
airborne route. A limitation in the design of the study is that the specific socio-
economic status of the included women is not known. The Cervical Cancer 
Screening Programme is population-based, i.e. all women of certain ages are 
invited. The catchment area of the Maternity Centers involved in this 
investigation comprises districts of both high and low socio-economic status. An 
analysis of drop-outs might have shown a relationship between socio-economic 
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status and the willingness to attend for screening, but this has not been carried 
out. 
 
In 2006 the participant rate in cytological cervical screening was 54-81% in 
different parts of Gothenburg, with a higher tendency to attend in districts with 
higher socio-economic status (Agneta Ellström: personal communication). 
Nevertheless, since no collected samples or data were patient-identifiable, all 
attending women were consecutively included. 
 
The utilised PCR methods have high sensitivity and specificity. Although most 
scientists are confident of these methods, some concern has been raised 
regarding the risk of contamination giving falsely positive results (186). 
However, this risk must now be considered to be very small since better routines 
and methods have been developed. The high sensitivity of PCR methods implies 
that even small amounts of DNA are detectable, and the identification of a 
possible pathogen might represent a remainder of a past infection, which is no 
longer active. This issue is important, for example in patients with C. 
trachomatis, who might receive falsely positive results if a NAAT test is 
performed too soon after antibiotic treatment. 
 
Detection of certain viruses in the genital area of both sexes is supportive of 
genital transmission. EBV has been detected in the genital area of both men and 
women (52, 68-70). CMV has been detected in cervical biopsies from four 
women with CMV cervicitis (59). However, CMV was not detected by PCR in 
urethral samples from 112 patients with urethritis (paper III). 
Unlike CMV, HSV-1 and HSV-2, which all are known to cause severe 
infections in newborns, the role of EBV in such infections remains to be 
substantiated. 
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Cervicitis and urethritis in women (Paper V)  
 
Cervicitis is the term for inflammation of the uterine cervix, but there is no 
generally accepted definition of this condition. The clinical signs mostly used 
for cervicitis in STI clinics in Scandinavia are visible mucopurulent secretion 
and easily induced bleeding of the cervical portio (187). The commonly used 
microscopical criterion for cervicitis in STI clinics is >30 PMNL per HPF in a 
stained cervical smear. An increased number of inflammatory cells in a vaginal 
wet smear is also used as a sign of inflammation, with a ratio PMNL:epithelial 
cells >1 interpreted as cervicitis (97). 
 
The most most commonly used definition of microscopic urethritis in women is 
≥5 PMNL per high power field (HPF) in ≥5 fields in 1000x magnification (121). 
 
The aim of paper V was to evaluate the association of the clinical signs of 
cervical inflammation ─ mucopurulent discharge and friability ─ and the 
microscopical signs of inflammation (above-mentioned) with a positive SDA 
test for Chlamydia trachomatis. Our results showed a statistically significant 
correlation (p<0.05) with C. trachomatis for mucopurulent discharge in the 
cervical portio, easily induced bleeding from the same locus and for more 
PMNL than epithelial cells in the vaginal wet smear. However, correlation was 
not shown between positivity for C. trachomatis and microscopical cervicitis or 
microscopical urethritis in stained smears (Table 2, paper V). 
 
In paper V the definition of microscopical cervicitis was >30 PMNL in a stained 
smear from the cervical orifice. The definition of microscopical urethritis was 
≥5 PMNL in the urethral smear. If the number of PMNL exceeded the number 
of epithelial cells in the vaginal wet smear, it was regarded as “positive”. 
Inflammatory cells in the vaginal wet smear may originate from both cervical 
and vaginal infections, and we preferred to regard a “positive” wet smear as a 
sign of “unspecific genital inflammation” rather than cervicitis and/or vaginitis. 
The definitions employed in our study are the ones used in many STI clinics in 
Scandinavia. 
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Comparison with other studies is complicated by varying diagnostic methods for 
C. trachomatis and differences in the prevalence of chlamydia and other STI in 
the studied populations. The literature on the association of various definitions 
of cervicitis and urethritis in women and chlamydia infection is inconsistent 
(188-190). 
 
According to the STI guidelines from CDC in 2010, cervicitis is characterized 
by mucopurulent discharge in the uterine cervix and/or easily induced 
endocervical bleeding. More than 10 PMNL/HPF on microscopic examination 
of a vaginal wet smear is said to be associated with chlamydia infection of the 
cervix. However, according to the CDC, an increased number of PMNL on an 
endocervical Gram stain has not been standardised in the diagnosis of cervicitis. 
Urethral smears are not mentioned in connection with chlamydia infection in 
women in the CDC guidelines (191). 
 
Marazzo et al. reported that inflammation in the endocervix or the urethra is 
associated with higher organism load and confers a higher likelihood of a 
positive diagnostic test for C. trachomatis (192). It is most likely that cases with 
a low bacterial load and discrete inflammatory signs were not diagnosed with C. 
trachomatis, when less sensitive diagnostic methods were used. This might 
contribute to the positive correlation between an increased number of PMNL in 
urethral and cervical smears and C. trachomatis in some older studies (189, 193-
195). 
However, also in two recent studies of female STI patients a correlation between 
≥5 PMNL in the urethral smear and chlamydia detected by more sensitive 
NAAT methods was observed (196, 197). Of our female patients with 
chlamydial infection, only 19.0% (8/42) had ≥5 PMNL in their urethral smears 
compared to 47.5% (19/40) in the study by Falk et al. in 2005. Of the 
chlamydia-negative women, 14.3% (6/42) in paper V compared to 25.4% 
(104/409) in Falk et al had microscopic urethritis. This notable difference could 
be due to inter- and intra-observer variation in the interpretation of 
microscopical smears, previously shown by Smith et al. (198). In a study from 
2003 of ten experienced microscopists, inter-observer consistency was found in 
97% of negative slides (<5 PMNL), 68% of low-grade slides (5-19 PMNL) and 
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94% of high-grade slides (>20 PMNL). Intra-observer concordance was 96% for 
negative smears, 75% for low-grade and 89% for highly positive smears (198). 
Among our patients only three women had urethral smears with >9 PMNL per 
HPF: thus the majority (11/14) of the smears assessed as urethritis were in the 
“low-grade” range, shown to be more difficult to estimate consistently compared 
to both oneself and other microscopists.  
 
Differences in the instruments and the sampling procedure could also be of 
importance. For the endocervical stained smears and the vaginal wet smears, the 
same sampling device was used in our study as in the studies by Moi et al. and 
Falk et al. (196, 197). However, these above-mentioned authors both used a 
blunt curette for the urethral smears, whereas we used a 1 µl plastic loop. This 
might have affected the outcome of the stained urethral smears. Nevertheless, 
since the aim of our study was to evaluate the value of different criteria of 
urethritis and cervicitis used in our clinical practice, all specimens were 
collected according to the standard procedure in the clinic. 
 
The selection of patients in our study is described in “Material and methods” as 
well as in paper V. The included patients all attended due to chlamydia partner 
notification, whereas the women described by Falk et al. were consecutive 
female STI patients attending for various reasons. It could be that patients 
attending due to partner tracing caught the infection more recently than 
unselected STI patients. If inflammatory signs evolve gradually from the time of 
transmission, fewer patients attending due to partner tracing would have high-
grade inflammatory smears. However, in a more recent study by Falk et al., 
comprising female patients attending due to chlamydia partner notification, 42% 
(15/36) of chlamydia-infected women had ≥5 PMNL in their urethral smears 
and 28% (10/36) had >9 PMNL per HPF (196). 
 
In clinical practice microscopy of urethral and endocervical smears is used to 
estimate the probability of STI in individual patients. The sensitivity of these 
smears to predict N gonorrhoeae is >95% in symptomatic men but lower in 
women and asymptomatic patients (40-60%) (199). The incidence of N. 
gonorrhoeae in Swedish women was 2.3 cases/100 000 women in 2010 (80). In 
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Swedish STI clinics, with a very low incidence of N. gonorrhoeae (<1%) in 
unselected patients, the smears are often utilized as part of the decision-making 
whether to give antibiotic treatment before the result of the chlamydia test is 
available. The sampling and examination of smears from the endocervix, vagina 
and urethra in STI patients take time and resources for a clinic. Nevertheless, it 
is important to perform a vaginal wet smear in female patients with symptoms or 
signs suggestive of candida, bacterial vaginosis or Trichomonas vaginalis 
infection. On suspicion of gonorrhoeae, endocervical and urethral stained 
smears are justified, since the specificity of visible gram negative diplococci for 
N. gonorrhoeae infection is 95-100% and the sensitivity of the diagnostic 
culture methods for Ng is 80-90% in women (1). 
 
The results of paper V may not be representative of women tested in other 
clinical settings or in countries with a different panorama of STI. In low-
prevalence populations and low-resource settings, presumptive diagnostic 
criteria may be used for selective screening. This is not the case in STI clinics 
with known high prevalences of C. trachomatis. However, routine sampling of 
smears from the cervix and the female urethra in unselected STI patients needs 
further evaluation. 
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CONCLUSIONS 
 
Papers I-II 
Herpes simplex type 2 infection was common in both STI patients and pregnant 
women. The estimated seroprevalence in pregnant women in Sweden (paper II) 
was not higher than in contemporary reports of pregnant women from other 
Nordic countries. HSV-2 infection is often asymptomatic or gives non-specific 
symptoms. HSV-2 antibody testing should be performed generously in patients 
with recurring, non-specific genital symptoms, if the results of PCR tests for 
HSV are negative. 
 
Paper III 
Epstein-Barr virus was significantly more common in urethral samples from 
patients with microscopical urethritis than in asymptomatic controls without an 
increased number of PMNL in the urethral smear. Correlation between EBV and 
urethritis has not been demonstrated earlier, but a possible causality between 
EBV and urethritis is still to be shown. 
 
Paper IV 
The detection of each of the viruses cytomegalovirus and Epstein-Barr virus in 
>10 % of cervical samples from young women supports sexual transmission of 
these viruses. The occurrence of EBV in >10% of the women emphasises the 
need for further investigation of congenital transmission of EBV. 
 
Paper V 
A significant correlation with a positive test for C. trachomatis was shown for 
mucopurulent discharge in the cervical portio, easily induced bleeding from the 
same locus and for more polymorph nuclear leucocytes (PMNL) than epithelial 
cells in the vaginal wet smear. However, correlation was not demonstrated 
between >30 PMNL in a stained smear from the cervix or ≥5 PMNL in a stained 
smear from the urethra and a positive test for C. trachomatis in female STI 
patients. Hence, routine sampling for microscopy from the cervix and the 
urethra in unselected female STI patients is questionable. 
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FUTURE PROSPECTS 
 
The panorama of infectious diseases varies between populations and time 
periods. Since the HSV-2 seroprevalence is correlated to sexual behaviour, it 
would be of importance to repeatedly follow the age-related seroprevalence of 
HSV-2 in the general population as well as in selected groups, such as STI 
patients and pregnant women. Changes in HSV-2 seroprevalence reflect sexual 
behaviour and might be used to estimate the long-term effect of preventive 
strategies. There is a strong correlation between HSV-2 and HIV and, especially 
in developing countries, the HSV-2 seroprevalence may contribute to 
comprehension of the STI/HIV epidemiology and to guiding preventive projects. 
Data on the epidemiology of HSV-2 infections also have implications for 
vaccine development. 
 
For improved understanding of the interaction of HSV-1 and HSV-2 infection, a 
long-term prospective study of first episodes of genital herpes with PCR as well 
as serological analysis at inclusion and at intervals further on would be of value.  
 
In paper III a correlation between the detection of EBV in urethral samples and 
microscopical urethritis was demonstrated, but a possible causal connection is 
still to be shown. Since EBV establishes latency, and thereby life-long infection, 
a curing treatment is hard to obtain, but an effective medical drug would 
otherwise be helpful to evaluate causality of EBV in urethritis. To more 
certainly distinguish active replication of EBV from passive latency would 
increase the probability of EBV as a causative agent in urethritis. 
 
In addition to its association with male urethritis, EBV was detected in the 
uterine cervix of young women (paper IV). Further support for EBV as a 
sexually transmitted agent would be gained if EBV were found in the genital 
area of sexual partners to those EBV positive individuals, especially if the same 
strains of EBV were found within sexual couples. 
 
Further studies of non-specific urethritis in men are needed to elucidate the 
etiology, the implications of an increased number of PMNL in urethral smear, 
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the risk of complications and indications for treatment and partner notification. 
Since health care resources are limited, and in consideration of our patients’ 
psycho-sexual well-being, asymptomatic men with non-infectious urethritis 
should ideally not be identified or at least distinguished from the ones with a 
treatable infection. Moreover, in the era of rising antibiotic resistance as a threat 
to public health, it is of utmost importance to reconsider our indications for 
antibiotic treatment. 
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